# MBX Biosciences

**Canonical:** https://apis.io/providers/mbx-biosciences/  
**Website:** https://www.mbxbio.com  
**APIs profiled:** 0

MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for endocrine and metabolic disorders, built on its proprietary PEPs platform. Lead programs include canvuparatide (MBX 2109) for hypoparathyroidism, plus MBX 4291, MBX 5765, and MBX 6XXX. Surfaced as a portfolio company of NEA and added to the API Evangelist network; no public API surface was found at this time.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Life Sciences, Biotechnology, Pharmaceuticals, Peptide Therapeutics, Endocrine and Metabolic, Clinical Stage

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/mbx-biosciences/). Scores are computed from the provider's own public artifacts under a published rubric.